Interaction between seroreactivity to microbial antigens and genetics in Crohn's disease: is there a role for defensins?
暂无分享,去创建一个
T. Molnár | M. Papp | Z. Tulassay | P. Lakatos | Y. Mándi | J. Papp | P. Miheller | I. Altorjay | L. Lakatos | J. Tumpek | Á. Kovács | K. Palatka | T. Szamosi | S. Fischer | Yvette Mándi | Tamás Molnár | Janos Papp | Mária Papp | Tamás Molnár
[1] T. Molnár,et al. New Serological Markers for Inflammatory Bowel Disease Are Associated With Earlier Age at Onset, Complicated Disease Behavior, Risk for Surgery, and NOD2/CARD15 Genotype in a Hungarian IBD Cohort , 2008, The American Journal of Gastroenterology.
[2] Y. Mándi,et al. Association of beta-defensin 1 single nucleotide polymorphisms with Crohn's disease , 2008, Scandinavian journal of gastroenterology.
[3] P. Lakatos,et al. Smoking in inflammatory bowel diseases: good, bad or ugly? , 2007, World journal of gastroenterology.
[4] F. Nagy,et al. NOD1 gene E266K polymorphism is associated with disease susceptibility but not with disease phenotype or NOD2/CARD15 in Hungarian patients with Crohn's disease. , 2007, Digestive and Liver Disease.
[5] M. Tremelling,et al. Gender-stratified analysis of DLG5 R30Q in 4707 patients with Crohn disease and 4973 controls from 12 Caucasian cohorts , 2007, Journal of Medical Genetics.
[6] G. Veres,et al. Seroreactivity to microbial components in Crohn's disease is associated with ileal involvement, noninflammatory disease behavior and NOD2/CARD15 genotype, but not with risk for surgery in a Hungarian cohort of IBD patients , 2007, Inflammatory bowel diseases.
[7] P. Rutgeerts,et al. Mutations in pattern recognition receptor genes modulate seroreactivity to microbial antigens in patients with inflammatory bowel disease , 2007, Gut.
[8] E. Oláh,et al. Germline MLH1 and MSH2 mutational spectrum including frequent large genomic aberrations in Hungarian hereditary non-polyposis colorectal cancer families: implications for genetic testing. , 2007, World journal of gastroenterology.
[9] K. Van Steen,et al. New serological markers in inflammatory bowel disease are associated with complicated disease behaviour , 2007, Gut.
[10] M. Papp,et al. Utility of serological markers in inflammatory bowel diseases: gadget or magic? , 2007, World journal of gastroenterology.
[11] S. Targan,et al. NOD2 variants and antibody response to microbial antigens in Crohn's disease patients and their unaffected relatives. , 2007, Gastroenterology.
[12] L. Sandoval-Ramírez,et al. Association of β-Defensin 1 Single Nucleotide Polymorphisms with Atopic Dermatitis , 2006, International Archives of Allergy and Immunology.
[13] P. Lakatos. Recent trends in the epidemiology of inflammatory bowel diseases: up or down? , 2006, World journal of gastroenterology.
[14] Z. Halpern,et al. Antibodies against laminaribioside and chitobioside are novel serologic markers in Crohn's disease. , 2006, Gastroenterology.
[15] N. Anthonisen,et al. Contribution of alpha- and beta-defensins to lung function decline and infection in smokers: an association study , 2006, Respiratory research.
[16] P. Rutgeerts,et al. DLG5 R30Q is not associated with IBD in Hungarian IBD patients but predicts clinical response to steroids in Crohn's disease. , 2006, Inflammatory bowel diseases.
[17] P. Lakatos,et al. Current concept on the pathogenesis of inflammatory bowel disease-crosstalk between genetic and microbial factors: pathogenic bacteria and altered bacterial sensing or changes in mucosal integrity take "toll" ? , 2006, World journal of gastroenterology.
[18] E. Louis,et al. The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Definitions and diagnosis. , 2006, Journal of Crohn's & colitis.
[19] J. Satsangi,et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. , 2005, Canadian journal of gastroenterology = Journal canadien de gastroenterologie.
[20] K. Fellermann,et al. Defensin deficiency, intestinal microbes, and the clinical phenotypes of Crohn’s disease , 2005, Journal of leukocyte biology.
[21] H. Drummond,et al. Sero-Reactivity to Microbial Components in Crohn's Disease Is Associated with Disease Severity and Progression, but not NOD2/CARD15 Genotype , 2004, The American Journal of Gastroenterology.
[22] A. Bousvaros,et al. Serologic Testing with ANCA, ASCA, and Anti-OmpC in Children and Young Adults with Crohn's Disease and Ulcerative Colitis: Diagnostic Value and Correlation with Disease Phenotype , 2004, The American Journal of Gastroenterology.
[23] M Schwab,et al. NOD2 (CARD15) mutations in Crohn’s disease are associated with diminished mucosal α-defensin expression , 2004, Gut.
[24] B. Sands,et al. A male with a pelvic mass , 2004, Gut.
[25] Thomas Lengauer,et al. Genetic variation in DLG5 is associated with inflammatory bowel disease , 2004, Nature Genetics.
[26] P. Lakatos,et al. Association of extraintestinal manifestations of inflammatory bowel disease in a province of western Hungary with disease phenotype: results of a 25-year follow-up study. , 2003, World journal of gastroenterology.
[27] T. Ganz. Defensins: antimicrobial peptides of innate immunity , 2003, Nature Reviews Immunology.
[28] M. Weichenthal,et al. Inducible and Constitutive &bgr;-Defensins Are Differentially Expressed in Crohn's Disease and Ulcerative Colitis , 2003, Inflammatory bowel diseases.
[29] S. Foster,et al. An essential role for NOD1 in host recognition of bacterial peptidoglycan containing diaminopimelic acid , 2003, Nature Immunology.
[30] T. C. White,et al. Single-Nucleotide Polymorphisms (SNPs) in Human β-Defensin 1: High-Throughput SNP Assays and Association with Candida Carriage in Type I Diabetics and Nondiabetic Controls , 2003, Journal of Clinical Microbiology.
[31] P. Rutgeerts,et al. Comparative study of ASCA (Anti-Saccharomyces cerevisiae antibody) assays in inflammatory bowel disease. , 2001, Gastroenterology.
[32] P. Rutgeerts,et al. Diagnostic value of anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease , 2001, American Journal of Gastroenterology.
[33] S. Targan,et al. Clinical utility of serodiagnostic testing in suspected pediatric inflammatory bowel disease , 2001, American Journal of Gastroenterology.
[34] S. Targan,et al. Anti-Saccharomyces cerevisiae mannan antibodies combined with antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease: prevalence and diagnostic role , 1998, Gut.
[35] R. Lehrer,et al. Widespread expression of beta‐defensin hBD‐1 in human secretory glands and epithelial cells , 1996, FEBS letters.
[36] M. Kerr,et al. Antibody to Saccharomyces cerevisiae (bakers' yeast) in Crohn's disease. , 1988, BMJ.
[37] J. Lennard-jones,et al. Classification of inflammatory bowel disease. , 1989, Scandinavian journal of gastroenterology. Supplement.